0001615774-16-007524.txt : 20161004
0001615774-16-007524.hdr.sgml : 20161004
20161004183023
ACCESSION NUMBER: 0001615774-16-007524
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160909
FILED AS OF DATE: 20161004
DATE AS OF CHANGE: 20161004
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc.
CENTRAL INDEX KEY: 0001651407
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472568632
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 GANSEVOORT STREET
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: 212-554-4366
MAIL ADDRESS:
STREET 1: 2 GANSEVOORT STREET
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oliviero James F III
CENTRAL INDEX KEY: 0001434718
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-55506
FILM NUMBER: 161920665
MAIL ADDRESS:
STREET 1: C/O KERYX BIOPHARMACEUTICALS, INC.
STREET 2: 750 LEXINGTON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
3
1
s104277_form3.xml
3
X0206
3
2016-09-09
0
0001651407
Checkpoint Therapeutics, Inc.
NONE
0001434718
Oliviero James F III
C/O CHECKPOINT THERAPEUTICS, INC.
2 GANSEVOORT STREET, 9TH FLOOR
NEW YORK
NY
10014
0
1
0
0
CEO and President
Common Stock (Restricted)
1000000
D
The shares of restricted stock vest as follows: One-third will vest over time in installments with one-half on October 13, 2017, one-fourth on October 13, 2018 and one-fourth on October 13, 2019. One-third of the shares will vest in three equal parts based on the Company's achievement of fully-diluted Market Capitalization of $250,000,000, $500,000,000, and $750,000,000 respectively. The final third will vest in two equal installments as follows: (i) one installment will vest upon the earlier of (A) the Company's first Corporate Development Transaction or (B) the first FDA approval of a Company product or medical device, and (ii) the second installment will vest upon the earlier of (A) the Company's second Corporate Development Transaction or (B) a second FDA approval of a Company product or medical device.
/s/ James F. Oliviero
2016-10-04